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Objectives: Progress in the therapy of malignant pleura| mesothelioma is
limited by the lack of an adequate staging system and controversy about 
prognostic factors. This surgical series was analyzed to determine whether 
a new TNM staging system proposed by the International Mesothelioma 
Interest Group and certain prognostic factors could stratify patients in 
future clinical trials. Methods: Thoracotomy was performed if computed 
tomographic scans showed resectable tumor confined to one hemithorax. 
Pleurectomy/decortication was done if visceral pleural tumor was minimal, 
and extrapleural pneumonectomy was done for more locally advanced 
disease. Complete resection was defined as no gross residual tumor. 
Adjuvant therapy was given as required by serial clinical trials. Patients 
had computed tomographic scans every 3 months until death. Prognostic 
factors were examined by log-rank and Cox regression analyses. Results: 
From October 1983 to July 1994, a total of 131 thoracotomies were 
performed, resulting in 101 resections, 72 of which were complete. Ex- 
trapleural pneumonectomy was done in 50 patients and pleurectomy/ 
decortication i 51. The ratio of men to women was 108:23. Median age was 
63 years (range 32 to 80 years). Operative mortality was five of 131 patients 
(3.8%), three of 50 in the group having extrapleural pneumonectomy (6%). 
Ninety-five of the 131 tumors were epithelial. Fifty-one of 89 patients (57%) 
having node dissections had diseased nodes, 45 (50%) N2. By univariate 
analysis, type of resection, T and N status, stage, histologic type, and 
adjuvant therapy, but not gender or age, significantly affected survival. 
Type of resection, stage, and histologic type were significant in a multivar- 
iate analysis. Local recurrence occurred mainly after pleurectomy/decorti- 
cation, and distant metastases developed after extrapleural pneumonec- 
tomy. Conclusions: (1) N2 nodal disease is more frequent han previously 
reported; (2) the prognostic importance of histologic type is confirmed; (3) 
both T and N status influence outcome, and the International Mesotheli- 
oma Interest Group staging system successfully identifies patients whose 
prognosis is poor; (4) despite more locally advanced disease in most 
patients with extrapleural pneumonectomy, that approach provided better 
local control than pleurectomy/decortication but failed to improve survival 
because of distant metastatic disease. Contrary to past practice, future 
clinical trials should stratify for histologic type, must control for TNM 
stage, and must consider the impact of type of surgical resection on the 
pattern of relapse. (J THORAC CARDIOVASC SURG 1996;111:815-26) 
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T he management of malignant pleural mesothe- lioma (MPM) remains a subject of controversy 
because of our poor understanding of the natural 
history of this disease and its apparent resistance to 
standard forms of therapy. Prospective clinical trials 
evaluating novel treatment strategies for MPM are 
needed but require an accurate, universally ac- 
cepted staging system that categorizes patients into 
relatively homogeneous groups. Since 1976, at least 
five staging systems for MPM have been proposed] 
Two of these ificlude specific descriptors of tumor 
node metastases (TNM), and the other three are 
based on a simple stage I through IV classifica- 
tion. 2-6 None of these systems is completely vali- 
dated or used uniformly for survival analyses. Re- 
cently, the International Mesothelioma Interest 
Group ( IMIG) developed a surgically based TNM 
staging system that reconciles and updates previous 
staging systems by taking into consideration emerg- 
ing information about the impact of T and N status 
on survival. 7However, even this new staging system 
is not fully validated. To evaluate whether it could 
accurately stratify patients in future clinical trials, 
we retrospectively applied the IMIG staging system 
to a large prospective surgical registry in which T 
and N status were carefully assessed and patients 
serially followed up. 
Patients and methods 
All patient s entered in this prospective registry had 
biopsy-proved MPM and had an exploratory thoracotomy 
done by the same surgeon (V.R.). The pathologic diagno- 
sis was always based on both histologic tumor type and 
immunohistochemistry. When necessary, electron micros- 
copy was added to confirm the diagnosis. Data collected in 
the registry included patient name, gender, age, date of 
operation, preoperative platelet count, type of procedure, 
extent of resection, tumor histologic type, extent of the 
primary tumor and presence of nodal metastases, opera- 
tive morbidity and mortality, type of adjuvant herapy, 
date and site of first relapse, and dates of latest follow-up 
or death with disease status. 
The primary tumor was considered potentially resect- 
able if preoperative computed tomographic scans of the 
chest and abdomen did not show extrathoracic disease, 
clear invasion of the mediastinal organs or chest wall, or 
extension through the diaphragm. The decision to per- 
form an extrapleural pneumonectomy as opposed to a 
pleurectomy/decortication for resection was based on the 
extent of visceral pleural tumor at thoracotomy. Ex- 
trapleural pneumonectomy, defined as an en-bloc resec- 
tion of the pleura, lung, ipsilateral diaphragm, and peri- 
cardium, s was performed for locally advanced isease, 
Usually in patients with confluent visceral pleural tumor 
not separable from the lung and a partially or totally fused 
pleural space. Pleurectomy/decortication, which removes 
all gross tumor without removing the underlying lung, was 
performed in patients who had minimal visceral plenral 
tumor. Partial parietal pleurectomy was sometimes per- 
formed for control of a pleural effusion if incompletely 
resectable tumor was found at exploration, but all pleu- 
rectomy/decortications a d extrapleural pneumonecto- 
mies were performed only if it was thought hat all gross 
tumor could be removed. Complete resection was defined 
as no gross residual tumor. Resection was defined as 
incomplete if any visible gross tumor remained at the 
completion of thoracotomy, even if only a few scattered 
tumor loci less than 5 mm in size were present. 
The recently developed IMIG staging system (Table I) 
was applied retrospectively to each patient o determine 
his or her TN status and corresponding tumor stage. 
Staging was based on precise information about tumor 
extent in the operative summary dictated by the attending 
surgeon and on nodal involvement as recorded in the 
pathology report. 
Many of the patients entered in this registry were also 
enrolled in three sequential prospective multisurgeon or 
multiinstitutional clinical trials. 9-11 Postoperative adjuvant 
therapy, if any, was determined by those trial protocols. 
Adjuvant chemotherapy was given only in the protocol 
setting. Patients not entered on a clinical trial usually 
received postoperative h mithoracic radiation. The total 
radiation dose and method of administration depended on 
whether a pneumonectomy was performed. 
Patients in whom thoracotomy disclosed unresectable 
tumor were followed up clinically until death. Patients 
who had a pleurectomy/decortication or extrapleural 
pneumonectomy were followed up by physical examina- 
tion and computed tomographic scans of the chest and 
abdomen every 3 months until the time of first recurrence. 
Additional imaging studies or biopsies were performed as 
necessary to document recurrent disease. Thereafter, 
these patients were also followed up clinically until the 
time of death. Thus accurate information is available 
about the first site of relapse in these patients, but not 
about all subsequent sites of relapse. 
Survival probabilities were calculated by the product 
limit method of Kaplan and Meier. 12 The prognostic 
significance of factors was tested in a univariate model by 
the log-rank statistic for categoric ovariates 13and by 
proportional hazards regression for continuous covari- 
ates. 14 Proportional hazards regression was used to test 
the prognostic significance of factors in a multivariate 
model. The p value was considered significant when it was 
less than 0.05. 
Results 
From October 1983 to July 1994, 131 consecutive 
patients with MPM underwent exploratory thoracot- 
omy, including 108 men and 23 women with a 
median age of 63 years (range 32 to 80 years). A 
total of 101 (77%) resections were performed, in- 
cluding 50 extrapleural pneumonectomies and 51 
pleurectomy/decortications. The resection was con- 
sidered complete in 72 patients (71% of resections, 
55% of all thoracotomies). The 30-day operative 
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Table I. New international staging system for diffuse malignant pleuraI mesothelioma, developed by the 
International Mesothelioma Interest Group 
T = Tumor 
T1 
Tla Tumor limited to the ipsilateral parietal including mediastinal and diaphragmatic pleura 
No involvement of the visceral pleura 
Tlb Tumor involving the ipsilateral parietal including mediastinal and diaphragmatic pleura 
Scattered foci of tumor also involving the visceral pleura 
T2 Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least 
one of the following features: 
• Involvement of diaphragmatic muscle 
• Confluent visceral pleural tumor (including the fissures), or extension of tumor from visceral pleura into the underlying 
pulmonary parenchyma 
T3 Describes locally advanced but potentially resectable tumor 
Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the 
following features: 
• Involvement of the endothoracic fascia 
• Extension into the mediastinal fat 
• Solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall 
• Nontransmural involvement of the pericardium 
T4 Describes locally advanced technically unresectable tumor 
Tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral) with at least one of 
the following features: 
• Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction 
• Direct transdiaphragmatic extension of tumor to the peritoneum 
• Direct extension of tumor to the contralateral p eura 
• Direct extension of tumor to one or more mediastinal organs 
• Direct extension of tumor into the spine 
• Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor 
involving the myocardium 
N = Lymph nodes 
NX Regional ymph nodes cannot be assessed 
NO No regional ymph node metastases 
N1 Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes 
N2 Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal thoracic nodes 
N3 Metastases in the contralateral mediastinal, contralateral internal thoracic, ipsilateral, or contralateral supraclavicular lymph 
nodes 
M = Metastases 
MX Presence of distant metastases cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
Stage I 
Ia Tla NO M0 
Ib Tlb NO M0 
Stage II T2 NO M0 
Stage III Any T3 M0 
Any N1 M0 
Any N2 M0 
Stage IV Any T4 
Any N3 
Any M1 
mortality rate was 3.8% (5/131 patients) and was 6% 
(3/50 patients) among the patients having extrapleu- 
ral pneumonectomy. The causes of death in the two 
patients who had a pleurectomy/decortication were 
a cerebrovascular ccident and multisystem failure 
related to massive bleeding in the upper gastroin- 
testinal tract from previously unsuspected peptic 
ulcer disease. The causes of death in the three 
patients who had an extrapleural pneumonectomy 
were massive pulmonary embolus, respiratory fail- 
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Table II. Postoperative complications in all 131 patients with MPM who underwent exploratory thoracotomy 
No. of patients experiencing complication 
according to type of procedure 
Type of Extrapleural pneumonectomy Pleurectomy/decortication Other Total no. of 
complication (n = 18) (n 13) (n = 2) complications 
Atrial arrhythmia 11 2 1 14 
Empyema 2 4 0 6 
Postoperative death 3 1 1 5 
Prolonged chest tube air leak 0 5 0 5 
Pneumonia 3 0 0 3 
Pulmonary embolus 1 1 0 2 
Respiratory failure 2 0 0 2 
Multisystem failure 1 1 0 2 
Renal failure (self-limited) 1 1 0 2 
Ventricular arrhythmia 0 1 0 1 
The number of complications i shown according to the type of surgical procedure performed. Because some patients had more than one complication, for 
example, bronchial stump leak and empyema, the total number of complications listed exceeds the number of patients. Eighteen of the extrapleural 
pneumonectomy group (36%) and 13 of the pleurectomy/decortication group (25.5%) had complications. Two patients undergoing other procedures had 
complications (7%). Ninety-eight patients had no complications. 
ure related to underlying interstitial lung disease, 
and respiratory failure from fulminant pneumonia 
related to underlying diabetes mellitus. 
The postoperative complications are shown in 
Table II and occurred in 33 of the 131 (25%) 
patients. The most common complication was atrial 
arrhythmia, which occurred in 11 of the patients 
having extrapleural pneumonectomy (22%) and two 
of those having pleurectomy/decortication (4%). 
According to the IMIG staging system, 18 pa- 
tients had T1 tumors, whereas 36 had T2, 45 had T3, 
and 32 had T4 tumors. Mediastina ! lymph node 
dissection was performed in 89 of the 101 (88%) 
patients undergoing resection. Fifty-one of these 
patients (57%) had nodal metastases and 45 (50%) 
had these metastases in the ipsilateral mediastinal 
lymph nodes (N2 disease). One patient had N3 
disease and five patients had only N1 disease. In 95 
of the 131 (76%) patients, the histologic tumor type 
was epithelial, whereas it was fibrosarcomatous in 
eight (6%) patients, of mixed cellularity in 26 (20%) 
patients, and desmoplastic n one patient. The his- 
tologic subtype was not specified in one patient. The 
preoperative platelet count was not uniformly re- 
corded during the first 5 years of this registry. It was 
known in 121 patients, of whom 41 were considered 
to have thrombocytosis because of a platelet count 
exceeding 400,000/ram 3. 
All 131 patients were included in the analyses of 
survival rates. The median follow-up for all 131 
patients was 9.4 months, 8.8 months for those having 
extrapleural pneumonectomy and 16.8 months for 
those having pleurectomy/decortication. The rela- 
tively short length of follow-up reflects the poor 
overall survivals in these patients, because they are 
all followed up until death. The median survival for 
patients categorized according to the type of surgi- 
cal resection, the tumor T and N status, stage, and 
histologic type is shown in Table III. The overall 
survivals according to these same variables are 
shown in Figs. 1 to 5. In univariate analyses the 
patients undergoing pleurectomy/decortication had 
a significantly better survival than did those under- 
going extrapleural pneumonectomy (p = 0.0054), 
and both  of these groups survived:significantlY 
longer than did patients who had a palliative pleu- 
rectomy or only an exploratory thoracotomy (Fig. 
1). The differences in survival according to T status 
(Fig. 2) were assessed by log-rank test across all T 
categories and were found to be significant (p = 
0.0058). Because of the small numbers of patients in 
each group, individual comparisons are inappropri- 
ate; hence T1/T2 was compared with T3/T4. Patients 
with T1/T2 status had a significantly better survival 
(p = 0.0079). Likewise, the small number of patients 
with either N1 or N3 disease necessitated that 
patients having NO disease be compared with those 
having N1-3 disease. Patients with N0 disease had a 
significantly better survival than did those with 
nodal metastases (p = 0.0074), in this case predom- 
inantly ipsilateral mediastinal nodal metastases (Fig. 
3). Because the overall and median survivals for T2 
and T3 tumors appeared relatively similar, these 
categories were further examined by N status (N0 
versus N1-3). No significant differences were de- 
tected in overall survivals for T2 NO versus T3 NO 
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(p = 0.77), for T2 N1-3 versus T3 N1-3 (p = 0.33), 
for T2 NO versus T2 N1-3 (p = 0.28), or for T3 NO 
versus T3 N1-3 (p = 0.07). However, as shown in 
Fig. 4, a trend toward worsening survival is related 
to both T and N status. The results of this analysis 
must be interpreted with caution because the num- 
ber of patients in these TN subsets is too small to 
yield statistically definitive results. 
The differences in survival by stage (Fig. 5) were 
assessed by log-rank test across all four stages and 
were found to be significant (p = 0.001). Fig. 5 
shows a trend of decreasing survival by stage, al- 
though individual comparisons between stages (forp 
value) are not justified by virtue of the small number 
of patients in each stage category. When stage I and 
II were grouped together they were associated with 
a significantly better survival than stages III and IV 
(p = 0.0001). Epithelial tumors were associated with 
a significantly better survival (p = 0.0002) than were 
tumors of other histologic types (Fig. 6). Thrombo- 
cytosis did not have an adverse effect on survival 
(Fig. 7). 
Patients who received any form of postoperative 
adjuvant herapy (n = 93) were compared in a 
univariate analysis with those who did not, and 
overall survival was significantly better in the former 
group. No significant difference in overall survival 
could be detected according to the type of adjuvant 
therapy, but the variation in treatment and the 
resultant small number of patients in each treatment 
category preclude a meaningful analysis. Univariate 
analyses also showed no significant difference in 
overall survival between complete and incomplete 
resection, between age less or greater than 50 or 
than 60 years, or between men and women. 
When a multivariate analysis was performed, only 
tumor stage (p = 0.0063), histologic type (p = 
0.0064), and type of surgical procedure still had a 
significant influence on overall survival. Although 
still significant, the difference in survival between 
pleurectomy/decortication and extrapleural pneu- 
monectomy was diminished in a multivariate analy- 
sis (p = 0.022). 
The sites of relapse in the 101 patients who had 
either an extrapleural pneumonectomy or a pleurec- 
tomy/decortication are shown in Table IV. Forty-six 
patients had a relapse in a single disease site, and 25 
had recurrent disease in multiple sites. Recurrences 
in the ipsilateral chest wall and mediastinum and in 
the region of previously resected pleura were seen in 
a few patients treated by extrapleural pneumonec- 
tomy but were far more common among those 
Table III. Median survival for all 131 patients 
according to TN status, stage, and histologic type 
Median survival (too) 
Operation 
Extrapleural pneumonectomy 9.9 
Pleurectomy/decortication 18.3 
T status 
T1 27 
T2 12 
T3 13 
T4 6.5 
N status 
N0 18.3 
N1-3 9.4 
Stage 
I 35 
II 16 
III 11.5 
IV 5.9 
Histologic type 
Epithelial 15.1 
Nonepithelial 6 
The median survival for the 101 patients who had either a pleurectomy/ 
decortication or extrapleural pneumonectomy is shown according to which 
operation was performed. 
having pleurectomy/decortication. The ipsilateral 
pleura was the single most common site of recurrent 
tumor after pleurectomy/decortication. In contrast, 
relapse in distant areas was more frequent after 
extrapleural pneumonectomy and occurred particu- 
larly in the contralateral p eura and lung, intraab- 
dominal organs, and peritoneum. 
Discussion 
For many years MPM was considered a rare and 
idiopathic ancer. Study of this disease did not begin 
in earnest until 1960, when Wagner, Slegg, and 
Marchand is established the link between asbestos 
exposure and the subsequent development OfMPM. 
The treatment of MPM has gained importance 
because it is becoming more prevalent worldwide 
and is still invariably fatal. 16 During the past 30 
years, our understanding of the epidemiology and 
pathology of MPM has been steadily improving. 17-2° 
However, our understanding of its natural history is 
still incomplete. The seemingly capricious behavior 
of MPM and its relative resistance to standard forms 
of cancer therapy often engender a sense of nihilism 
and an ad hoc approach to treatment. 21-25 
The critical importance of an accurate staging 
system and of identifying significant prognostic fac- 
tors is well accepted in the study and treatment of all 
other solid tumors. In MPM, some prognostic fac- 
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Fig. 1. Univariate analysis of overall survival according to type of surgical procedure performed. When 
pleurectomy/decortication was compared with extrapleural pneumonectomy, p was 0.0054. 
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Fig. 2. Univariate analysis of overall survival by T status. When T1/T2 was compared with T3/T4, p was 
0.0079. When all four T groups were compared simultaneously, p was 0.0058. 
tors have been identified, but no universally ac- 
cepted staging system exists. During the past 20 
years, at least five systems have been proposed. 2-6 
None is fully validated or consistently used for 
survival analyses. The recently developed IMIG 
staging system reconciles and updates earlier staging 
systems and provides precise TNM descriptors that 
can be used for radiographic, surgical, and patho- 
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logic staging of MPM. Although based on emerging 
information about the impact of T and N status on 
survival, the IMIG system is also not fully validated 
by large surgical series of patients with carefully 
staged disease. In particular, the adverse influence 
of nodal metastases on survival is reported in one 
surgical series 3 but not in others. 26 Our experience 
indicates that the IMIG staging system does stratify 
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patients appropriately according to prognosis, and it 
confirms the adverse influence of both advanced T 
status and nodal metastases on overall survival. 
Moreover, the frequency of N2 disease in this series 
is higher than reported previously; and suggests that 
complete mediastinal lymph node dissection or sam- 
pling is important in accurately determining disease 
stage. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 4 
Rusch and Venkatraman 8 2 3 
o. 
o 
> 
~d 
< 400,000 (n = 80) 
.. . . . . . .  > 400,000 (n = 41) 
~~l  II, 
i...._~- .................. 
[ ~""+ . . . . . . . . . . . . . . . . . . . . .  + 
I 
I I I I I 
10 20 30 40 50 
Time (in months) 
eq o 
60 
Fig. 7. Univariate analysis of overall survival by preoperative platelet count. Thrombocytosis does not 
have a significant effect on survival (p > 0.05). 
The systematic use of a staging system such as the 
IMIG system could help resolve the controversies 
surrounding the treatment of MPM. For instance, 
some authors argue that patients with MPM should 
receive only supportive care 21' 23, 24 because the nat- 
ural history of MPM is variable and because no 
therapeutic modality appears to improve life expect- 
ancy. Yet recent data, particularly from the thora- 
coscopic experience of Boutin and associates, 27'2s 
suggest hat the variation in survivals reported 
with supportive care alone is largely explained by 
the stage of disease at diagnosis and the histologic 
tumor type. Grouping together all patients with 
MPM regardless of these factors is analogous to 
grouping together patients with T1 NO and stage 
IV non-small-cell ung cancer. No therapeutic 
modality can be properly assessed unless applied 
to groups of patients with a relatively homoge- 
neous prognosis. 
The routine use of a TNM staging system could 
also resolve controversy over the choice of opera- 
tion for patients who have potentially resectable 
MPM. For patients with more locally advanced 
tumor and extensive visceral pleural disease, only 
extrapleural pneumonectomy allows complete re- 
section of all gross disease. However, for patients 
with minimal visceral pleural tumor, pleurectomy/ 
decortication was advocated as a safer operation 
Table IV. First sites of recurrent disease 
Single site Multiple sites 
(IV = 46) (N = 25) 
Site of relapse EPP P/D EPP P/D 
Ipsilateral "pleura" 2 18 3 7 
Contralateral pleura 6 2 3 0 
Ipsilateral lung - -  2 - -  1 
Contralateral lung 3 0 4 1 
Pericardium 1 0 1 0 
Myocardium 0 0 0 0 
Mediastinum 0 0 6 2 
Chest wall 2 3 6 2 
Intra-abdominal, visceral 3 0 2 3 
Peritoneum 2 0 3 5 
Central nervous ystem 0 0 0 0 
Retroperitoneum 1 0 1 0 
Other 0 1 1 0 
First sites of relapse in the 71 patients who underwent either extrapleural 
pneurnonectorny (EPP) or pleurectomy/decortication (P/D) and then had 
recurrent disease. Forty-six patients had a relapse in a single disease site 
and 25 patients had relapses in multiple sites. The sites of relapse are 
displayed according to the type of surgical resection performed. 
than extrapleural pneumonectomy, which previously 
had a reported mortality rate of 15% to 30%. 4,9 
Recent experience showing that the mortality rate of 
extrapleural pneumonectomy can be reduced to less 
than 10% 26, 29 has further fueled this controversy. 
Another aspect of this controversy is that the choice 
of operation has important implications for the use 
824 Rusch and Venkatraman 
The Journal of Thoracic and 
Cardiovascular Surgery 
April 1996 
of adjuvant postoperative radiation. Hemithoracic 
radiation can be administered to a higher total dose 
after extrapleural pneumonectomy than after pleu- 
rectomy/decortication.30,31 If a treatment regimen 
of surgical resection and postoperative radiation is 
planned, pleurectomy/decortication in patients with 
very early tumor offers a lower early mortality but 
potentially less effective adjuvant herapy, whereas 
extrapleural pneumonectomy offers a higher early 
mortality but potentially more effective radiotherapy. 
Our experience confirms that the operative mor- 
tality of extrapleural pneumonectomy, although still 
higher than for a pleurectomy/decortication, is sim- 
ilar to that of a standard pneumonectomy in the 
hands of surgeons or single institutions that perform 
this operation frequently. However, when consid- 
ered solely in a univariate analysis, pleurectomy/ 
decortication in this series was associated with a 
better overall survival than extrapleural pneumonec- 
tomy. The application of a multivariate analysis to 
survival suggests that the type of surgical resection is 
much less important when considered in the context 
of stage and histology. Previous attempts to deter- 
mine the relative benefit of extrapleural pneumo- 
nectomy versus pleurectomy/decortication have not 
truly taken TN status into account. Our experience 
emphasizes the importance of controlling for stage 
and histology when assessing surgical results. 
Our data also corroborate a previous report from 
the Lung Cancer Study Group 9 suggesting that 
distant metastases may be the initial site of relapse 
more frequently after extrapleural pneumonectomy 
than after pleurectomy/decortication. H wever, this 
could also reflect he disease stage and prevalence of 
nodal metastases. These findings need to be exam- 
ined further in larger numbers of patients in whom 
the disease has been carefully staged. 
No TNM staging system fully recognizes the 
pathologic and biologic variables that influence sur- 
vival. Many factors are reported to be prognostic in 
MPM, including histologic type, age, gender, perfor- 
mance status, length of time to diagnosis, type of 
symptoms, completeness of surgical resection, 
weight loss, history of asbestos exposure, and plate- 
let count. 2s' 32-36* Some purported prognostic factors 
including the type of symptoms, weight loss, and 
performance status reflect umor stage and were not 
examined in this analysis. No effect of age or gender 
on survival was found in our experience, but the 
influence of gender is difficult to assess because of 
* Chahian AP: Personal communication. 
the small number of women in this series. The lack 
of effect of complete resection on overall survival 
could be related to the stringent definition used in 
this series. Incomplete resection described patients 
who had minimal gross residual tumor, usually 
scattered islands of tumors less than 5 mm in size. 
Patients who would have had more extensive resid- 
ual tumor were simply not offered resection with 
curative intent. Importantly, our experience con- 
firms the beneficial impact of epithelial histology, 
which has been the most consistent prognostic fac- 
tor across all reported series. 
In summary, this experience with patients in 
whom the extent of disease was carefully staged at 
thoracotomy suggests that the new IMIG staging 
system for MPM accurately classifies patients ac- 
cording to prognosis. Current information about he 
impact of N1 versus N2 nodal metastases is inade- 
quate to distinguish between involvement of these 
two nodal groups. In this series, N1 nodes in the 
resected specimen were not always specifically ex- 
amined by the pathologist; herefore the true prev- 
alence of N1 disease is unknown. It is possible that 
N2 nodes are involved earlier or more frequently in 
MPM because the tumor arises in the parietal 
pleura and involves the entire pleural space. The 
differential influence of N1 and N2 nodes should be 
examined in future surgical series. The importance 
of histologic type is confirmed and suggests that 
patients hould be stratified according to whether 
they have epithelial tumors or one of the other 
histologic subtypes of MPM. Additional careful 
clinicopathologic correlation in large prospective 
surgical series is needed to test the validity of the 
IMIG staging system and to determine whether the 
T and N descriptors should be revised or combined 
into broader stage classifications. For example, it is 
possible that the T2 and T3 categories will prove to 
have overall survivals that are sufficiently similar to 
warrant collapsing these descriptors into a single 
group. Likewise, much more information is 
needed about the prevalence of N1 and N3 nodal 
metastases and the influence of these nodal 
groups on outcome. However, at present the 
analysis of this series suggests that future clinical 
trials should include careful TNM staging with the 
IMIG system and stratification by histologic type 
to assess whether new treatment strategies alter 
overall survival. 
We thank Melody Owens for her assistance in data 
management and the preparation of this manuscript. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 4 
Rusch and Venkatraman 8 2 5 
REFERENCES 
1. Dimitrov NV, McMahon S. Presentation, diagnostic meth- 
ods, staging, and natural history of malignant mesothelioma. 
In: Antman K, Aisner J, eds. Asbestos-related malignancy. 
Orlando: Grune & Stratton, 1987:225-38. 
2. Chahinian AP. Therapeutic modalities in malignant pleural 
mesothelioma. In: Chretien J, Hirsch A, eds. Diseases of the 
pleura. New York: Masson, 1983:224-36. 
3. Sugarbaker D J, Strauss GM, Lynch TJ, et al. Node status has 
prognostic significance in the multimodality therapy of dif- 
fuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-8. 
4. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleu- 
ropneumonectomy in the management of diffuse malignant 
mesothelioma of the pleura: experience with 29 patients. 
Thorax 1976;31:15-24. 
5. Mattson K. Natural history and clinical staging of malignant 
mesothelioma [Abstract]. Eur J Respir Dis 1982;63(Suppl 
124):87. 
6. Rusch VW, Ginsberg RJ. New concepts in the staging of 
mesotheliomas. In: Deslauriers J, Lacquet LK, eds. Thoracic 
surgery: surgical management of pleural diseases. St. Louis: 
Mosby, 1990:336-43. 
7. Rusch VW, The International Mesothelioma Interest Group. 
a proposed new international TNM staging system for ma- 
lignant pleural mesothelioma. Chest [In press]. 
8. Rusch VW, Dillard D. Pleural mesothelioma. In: Pearson 
FG, Deslauriers J, Ginsberg RJ, Hiebert CA, McKneally MF, 
Urschel HC, eds. Thoracic surgery. New York: Churchill 
Livingstone, 1995:1083-105. 
9. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleu- 
rai pneumonectomy in malignant pleural mesothelioma. J 
THORAC CARDIOVASC SURG 1991;102:1-9. 
10. Rusch VW, Saltz L, Venkatraman E, et al. A phase II trial of 
pleurectomy/decortication followed by intrapleural and sys- 
temic chemotherapy for malignant pleural mesothelioma. J 
Clin Oncol 1994;12:1156-63. 
11. Rusch V, Livingston R. Radical decortication, intraoperative 
intrapleural cisplatin (CDDP) and post-operative systemic 
chemotherapy for malignant pleural mesothelioma (MM) 
[Abstract]. Proc Am Soc Clin Oncol 1989;8:219. 
12. Kaplan EL, Meier P. Nonparametric estimation from incom- 
plete observations. J Am Stat Assoc 1958;53:457-81. 
13. Mantel N, Haenszel W. Statistical aspects of the analysis of 
data from retrospective studies of disease. J Natl Cancer Inst 
1958;22:718-48. 
14. Cox DR. Regression models and life tables [with discussion]. 
J R Stat Soc B 1972;34:187-220. 
15. Wagner JC, Slegg CA, Marchand P. Diffuse pleural mesothe- 
liomas and asbestos exposure in Northwestern Cape Prov- 
ince. Br J Ind Med 1960;17:260-71. 
16. Spirtas R, Connelly RR, Tucker MA. Survival patterns for 
malignant mesothelioma: the SEER experience. Int J Cancer 
1988;41:525-30. 
17. Wagner JC. Mesothelioma and mineral fibers. Cancer 1986; 
57:1905-11. 
18. Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, 
Bernatz PE. Diffuse malignant mesothelioma of pleura: 
diagnosis and survival in 92 cases. Cancer 1986;58:1540-51. 
19. Nauta RJ, Osteen RT, Antman KH, Koster JK. Clinical 
staging and the tendency of malignant pleural mesotheliomas 
to remain localized. Ann Thorac Surg 1982;34:66-70. 
20. Wirth PR, Legier J, Wright GL Jr. Immunohistochemical 
evaluation of seven monoclonal ntibodies for differentiation 
of pleural mesothelioma from lung adenocarcinoma. Cancer 
1991;67:655-62. 
21. Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-War- 
wick M. Malignant mesothelioma of the pleura: a study of 52 
treated and 64 untreated patients. Thorax 1984;39:255-9. 
22. Lewis RJ, Sisler GE, Mackenzie JW. Diffuse, mixed malig- 
nant pleural mesothelioma. Ann Thorac Surg 1981;31:53-60. 
23. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van Der 
Merwe CA. Malignant pleural mesothelioma:  disease un- 
affected by current therapeutic maneuvers. J Clin Oncol 
1988;6:527-35. 
24. Achatzy R, Beba W, Ritschler R, et al. The diagnosis, therapy 
and prognosis of diffuse malignant mesothelioma. Eur J 
Cardiothorac Surg 1989;3:445-8. 
25. Hulks G, Thomas JStJ, Waclawski E. Malignant pleural 
mesothelioma in western Glasgow 1980-6. Thorax 1989;44: 
496-500. 
26. Allen KB, Faber LP, Warren WH. Malignant pleurai me- 
sothelioma: extrapleural pneumonectomy and pleurectomy. 
Chest Surg Clin North Am 1994;4:113-26. 
27. Boutin C, Rey F. Thoracoscopy in pleural malignant me- 
sothelioma: a prospective study of 188 consecutive patients. 
Part 1: Diagnosis. Cancer 1993;72:389-93. 
28. Boutin C, Rey F, Gouvernet J, Viallat J-R, Astoul P, Ledoray 
V. Thoracoscopy in pleural malignant mesothelioma:  pro- 
spective study of 188 consecutive patients. Part 2: Prognosis 
and staging. Cancer 1993;72:394-404. 
29. Sugarbaker D J, Heher EC, Lee TH, et al. extrapleural 
pneumonectomy, chemotherapy, and radiotherapy in the 
treatment of diffuse malignant pleural mesothelioma. J THO- 
RAC CARDIOVASC SURG 1991;102:10-5. 
30. Maasilta P. Deterioration i  lung function following hemi- 
thorax irradiation for pleural mesothelioma. Int J Radiation 
Oncol Biol Physiol 1991;20:433-8. 
31. Mychalczak BR, Nori D, Armstrong JG, Martini N, Harrison 
LB. Results of treatment of malignant pleuraI mesothelioma 
with surgery, brachytherapy, and external beam irradiation 
[Abstract]. Proceedings of the American Endocurietherapy 
Society 1989;12. 
32. Tammilehto L. Malignant mesothelioma: prognostic factors 
in a prospective study of 98 patients. Lung Cancer 1992;8: 
175-84. 
33. Pogrebniak H, Temeck B, Steinberg S, Kranda K, Pass H. 
Cisplatin, interferon, and tamoxifen for primary and adjuvant 
use in malignant pleural mesothelioma. Ann Surg Oncol [In 
press]. 
34. RuNe R, Feld R, Minkin S, et al. Diffuse malignant mesothe- 
lioma of the pleura in Ontario and Quebec: a retrospective 
study of 332 patients. J Clin Oncol 1989;7:1157-68. 
35. Antman KH, Shemin R, Ryan L, et al. Malignant mesothe- 
lioma: prognostic variables in a registry of 180 patients, the 
Dana-Farber Cancer Institute and Brigham and Women's 
Hospital experience over two decades, 1965-1985. J Clin 
Oncol 1988;6:147-53. 
36. Chahinian AP, Pajak TF, Holland JF, Norton L. Diffuse 
malignant mesothelioma: prospective valuation of 69 pa- 
tients. Ann Intern Med 1982;96(6, Pt 1):746-55. 
Discuss ion 
Dr. Douglas J. Mathisen (Boston, Mass.). Can you explain 
the difference between palliative pleurectomy and pleurec- 
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tomy/decortication? There was a survival difference, and I 
think it would be important to explain this difference. 
Dr. Rusch. Patients who had a pleurectomy/decortica- 
tion with therapeutic intent had all or almost all gross 
tumor removed. Patients who had a "palliative" pleurec- 
tomy had an exploratory operation in which the intent was 
to resect, but the tumor could not be completely removed 
and only a parietal pleurectomy was done to control the 
effusion. Thus "palliative" pleurectomy was a much less 
extensive resection. 
Dr. Malcolm M. DeCamp (Boston, Mass.). Your paper 
underscores one of the universal problems in mesotheli- 
oma--tlying to determine who should receive aggressive 
surgical therapy and who should receive palliative therapy 
with less invasive techniques. In this retrospective s ries, 
how hard was it to get your pathologists to evaluate 
pleurectomy specimens and assign them specific T stages? 
You have carefully defined T in terms of 1A, 1B, 2, and so 
on. Was that difficult? We have a difficult problem getting 
our pathologists o accurately evaluate depth of invasion 
at so many different margins. 
Dr. Rusch. I think it is difficult, perhaps impossible, for 
pathologists o examine margins in this disease, although 
I am aware that at the Brigham there has been an effort to 
do so. This staging system is primarily designed to stage 
the disease surgically either at thoracoscopy or thoracot- 
omy. The T status is established by the surgical findings, 
not necessarily the pathologic findings. The N status, of 
course, is established pathologically. 
Dr. Robert J. Ginsberg (New York, N.Y.). It has been 
about 30 years since the first attempt at staging mesothe- 
lioma was made. As Dr. Rusch rightly pointed out, there 
are six or seven staging systems, and every article espouses 
a different staging system. In 1985, when we adopted the 
new staging system for lung cancer, it was not difficult for 
us to quickly adapt it to all reports. In fact, the two 
American thoracic surgical journals agreed that within 1 
year the new staging system had to be used in all reported 
results of lung cancer. I would urge that everybody 
reporting their results of mesothelioma use this new 
staging system, which does seem to apply and is similar to the 
TNM staging system that was proposed with some modifi- 
cations. It would be worthwhile for our journals to accept 
only articles reported in the new staging system. All of the 
data that Dr. Rusch analyzed were restaged from the pathol- 
ogy reports. It is not that difficult to analyze the surgical 
staging and the pathologic staging from these reports and 
reclassify them according to this new staging system. 
Dr. Ruseh. Thank you for the endorsement. I would 
emphasize that the IMIG does not consider this a perfect 
staging system. We realize this is a first pass. We hope that 
the application of this staging system both retrospectively 
and prospectively will enable us to refine it just as has 
been done for non-small-cell cancer. 
